Seeking Alpha

Sarepta Therapeutics: Why Today's Rally On DMD Drug Label Expansion Won't Last

Sarepta Therapeutics' gene therapy Elevidys has been granted label extension to treat Duchenne Muscular Dystrophy patients aged 4 and above. Sarepta Therapeutics stock price soars over 30% to >$160 ...
FiercePharma

Sarepta enjoys early sales ramp for DMD gene therapy, maintains confidence in label expansion

The third quarter marked a momentous one for Sarepta Therapeutics, bringing the long-anticipated launch of its Duchenne muscular dystrophy (DMD) gene therapy Elevidys. After traveling a tumultuous ...
Briefing.com

Sarepta Therapeutics soars on label expansion for DMD therapy, says opportunity is immense (SRPT)

Sarepta Therapeutics (SRPT +36%) is surging after announcing that the FDA approved an expansion to the labeled indication for ELEVIDYS. Sarepta, which is a leader in precision genetic medicine for ...
BioWorld

EMA expands Translarna DMD label while nixing Exondys application

DUBLIN – The curious gap in understanding between the FDA and the EMA on which drugs work in Duchenne muscular dystrophy (DMD) and which drugs don't widened last week, as the EMA's Committee on Human ...
Investing

Sarepta’s DMD gene therapy receives updated label with safety warnings

CAMBRIDGE, Mass. - Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced Friday that the prescribing information for ELEVIDYS, its gene therapy for Duchenne muscular dystrophy (DMD), has been updated ...
BioWorld

Open-label sesame: Seeds of phase III Catabasis win in DMD sown – or maybe

BioWorld - Monday, October 30, 2023 See today's BioWorld Home » Open-label sesame: Seeds of phase III Catabasis win in DMD sown – or maybe Subscribe to BioWorld™ news services See subscription options ...